For more insights on the scope and value chain analysis, Read a FREE Sample Report
Key Considerations for Market Forecast:
- Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
- Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
- Pre- as well as post-COVID-19 market estimates
- Quarterly impact analysis and updates on market estimates
Key Market Participants Analysis
Alkermes Public Ltd. Co.
The company is focused on developing innovative medicines that aim to address the unmet needs of people living with serious mental illness, addiction, and cancer. The company offers narcolepsy drugs such as ALKS 2680 tablets
Avadel Pharmaceuticals plc
The company offers narcolepsy drugs such as FT218 tablets.
Axsome Therapeutics Inc.
Under this segment, the company develops novel therapies for the management of CNS disorders. The company offers narcolepsy drugs such as Sunosi tablets.
BIOPROJET
The company manufactures and supplies prescription-only medication throughout the world. The company offers narcolepsy drugs such as Wakix which is a histamine H3 receptor antagonist.
Jazz Pharmaceuticals Plc
The company operates in a single segment involved in the identification, development, and commercialization of meaningful pharmaceutical products that address unmet medical needs. The company offers narcolepsy drugs such as Xywav tablets.
Download Sample PDF for Vendor-specific insights and their initiatives
Narcolepsy Drugs Market Segmentation Highlights
- Type
- Narcolepsy With Cataplexy: The narcolepsy drugs market share growth in the narcolepsy with cataplexy segment will be significant during the forecast period. The onset of narcolepsy with cataplexy is usually during the teenage and young adulthood years and persists throughout the lifetime. Pathophysiological studies have shown that the disease is caused by the early loss of neurons in the hypothalamus that produce hypocretin, a wakefulness-associated neurotransmitter, present in cerebrospinal fluid. The treatment includes stimulant drugs to suppress daytime sleepiness, antidepressants for cataplexy, and gamma-hydroxybutyrate for both symptoms. Moreover, the rising cases of narcolepsy with cataplexy will boost the market growth during the forecast period.
- Narcolepsy Without Cataplexy
- Secondary Narcolepsy
- Geography
- North America: 44% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the narcolepsy drugs market in North America. Market growth in this region will be slower than the growth of the market in Asia. The high per capita pharmaceutical expenditure will facilitate the narcolepsy drugs market growth in North America over the forecast period.
- Europe
- Asia
- Rest Of World (ROW)
Download Segment-wise Insights and Regional Opportunities in this PDF Sample
Related Reports
Curing Agent Market by Type and Geography - Forecast and Analysis 2022-2026
Quinidine Sulfate Market by Disease Type and Geography - Forecast and Analysis 2022-2026
Narcolepsy Drugs Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.1% |
Market growth 2022-2026 |
$ 1.60 billion |
Market structure |
Fragmented |
YoY growth (%) |
8.5 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key consumer countries |
US, Canada, Germany, UK, and France |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Alkermes Public Ltd. Co., Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., BIOPROJET, Cadila Pharmaceuticals Ltd., Don Valley Pharma, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals Plc, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., Shionogi and Co. Ltd., Somacare, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Content
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Narcolepsy with cataplexy - Market size and forecast 2021-2026
- Exhibit 28: Chart on Narcolepsy with cataplexy - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Narcolepsy with cataplexy - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Narcolepsy with cataplexy - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Narcolepsy with cataplexy - Year-over-year growth 2021-2026 (%)
- 5.4 Narcolepsy without cataplexy - Market size and forecast 2021-2026
- Exhibit 32: Chart on Narcolepsy without cataplexy - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Narcolepsy without cataplexy - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Narcolepsy without cataplexy - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Narcolepsy without cataplexy - Year-over-year growth 2021-2026 (%)
- 5.5 Secondary narcolepsy - Market size and forecast 2021-2026
- Exhibit 36: Chart on Secondary narcolepsy - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Secondary narcolepsy - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Secondary narcolepsy - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Secondary narcolepsy - Year-over-year growth 2021-2026 (%)
- 5.6 Market opportunity by Type
- Exhibit 40: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 France - Market size and forecast 2021-2026
- Exhibit 78: Chart on France - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on France - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on France - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on France - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 86: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 87: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification
- 10.3 Alkermes Public Ltd. Co.
- Exhibit 89: Alkermes Public Ltd. Co. - Overview
- Exhibit 90: Alkermes Public Ltd. Co. - Product / Service
- Exhibit 91: Alkermes Public Ltd. Co. - Key news
- Exhibit 92: Alkermes Public Ltd. Co. - Key offerings
- 10.4 Avadel Pharmaceuticals plc
- Exhibit 93: Avadel Pharmaceuticals plc - Overview
- Exhibit 94: Avadel Pharmaceuticals plc - Business segments
- Exhibit 95: Avadel Pharmaceuticals plc - Key news
- Exhibit 96: Avadel Pharmaceuticals plc - Key offerings
- Exhibit 97: Avadel Pharmaceuticals plc - Segment focus
- 10.5 Axsome Therapeutics Inc.
- Exhibit 98: Axsome Therapeutics Inc. - Overview
- Exhibit 99: Axsome Therapeutics Inc. - Product / Service
- Exhibit 100: Axsome Therapeutics Inc. - Key offerings
- 10.6 BIOPROJET
- Exhibit 101: BIOPROJET - Overview
- Exhibit 102: BIOPROJET - Product / Service
- Exhibit 103: BIOPROJET - Key offerings
- 10.7 Jazz Pharmaceuticals Plc
- Exhibit 104: Jazz Pharmaceuticals Plc - Overview
- Exhibit 105: Jazz Pharmaceuticals Plc - Product / Service
- Exhibit 106: Jazz Pharmaceuticals Plc - Key news
- Exhibit 107: Jazz Pharmaceuticals Plc - Key offerings
- 10.8 Shionogi and Co. Ltd.
- Exhibit 108: Shionogi and Co. Ltd. - Overview
- Exhibit 109: Shionogi and Co. Ltd. - Product / Service
- Exhibit 110: Shionogi and Co. Ltd. - Key offerings
- 10.9 Somacare
- Exhibit 111: Somacare - Overview
- Exhibit 112: Somacare - Product / Service
- Exhibit 113: Somacare - Key offerings
- 10.10 Takeda Pharmaceutical Co. Ltd.
- Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 116: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 117: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 10.11 Teva Pharmaceutical Industries Ltd.
- Exhibit 118: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 119: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 120: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 121: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 122: Teva Pharmaceutical Industries Ltd. - Segment focus
- 10.12 XWPharma Ltd.
- Exhibit 123: XWPharma Ltd. - Overview
- Exhibit 124: XWPharma Ltd. - Product / Service
- Exhibit 125: XWPharma Ltd. - Key offerings
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 126: Inclusions checklist
- Exhibit 127: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 128: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 129: Research methodology
- Exhibit 130: Validation techniques employed for market sizing
- Exhibit 131: Information sources
- 11.5 List of abbreviations
- Exhibit 132: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article